Last clinical review
By GLP1Zoom editorial board
Loading content…
Condition
Cardiovascular Risk Reduction
Several GLP-1 RAs carry FDA indications for reducing cardiovascular events. Wegovy received a 2024 SELECT-based indication to reduce MACE in adults with CVD and overweight/obesity. Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
Quick answer
UpdatedCardiovascular disease (CVD) is the leading cause of US death — ~700,000 annually, ~50% of US adults have at least one major CVD risk factor (hypertension, obesity, diabetes, dyslipidemia). Several GLP-1s have FDA approvals for cardiovascular event reduction: Wegovy (SELECT trial 20% MACE reduction in obese non-diabetic CVD patients), Ozempic (SUSTAIN-6 26% MACE reduction), Trulicity (REWIND 12%), Victoza/Liraglutide (LEADER 13%).
- US prevalence: ~127 million adults with at least one CVD risk factor
- AHA Heart Disease & Stroke Statistics 2024
- Annual US deaths: ~700,000
- CDC leading-cause-of-death data
- Wegovy CV benefit: 20% MACE reduction (SELECT)
- Adults with obesity/overweight + established CVD
- Ozempic CV benefit: 26% MACE reduction (SUSTAIN-6)
- Adults with T2D + established CVD
- Standard CVD therapy: Statins + antihypertensives + lifestyle
- GLP-1s are adjuncts for eligible patients